← Back to Clinical Trials
Recruiting NCT06294184

NCT06294184 TDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06294184
Status Recruiting
Phase
Sponsor Guangzhou Psychiatric Hospital
Condition Subthreshold Depression
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2023-11-01
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 25 Years
Study Type INTERVENTIONAL
Interventions
tdcs lDLPFCtdcs rVLPFCSham

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2023-11-01 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess the mechanisms of the effect of transcranial direct current stimulation (tDCS) in alleviating subthreshold depressive symptoms in young individuals, and individualized outcome prediction is carried out.

Eligibility Criteria

Inclusion Criteria: * 1\) Be between the ages of 12-25; * 2\) is right-handed on the Edinburgh Handedness Inventory; * 3\) 2-4 of the 9 depressive symptoms defined by the American Diagnostic and Statistical Manual of Diseases, Fifth Edition (DSM-5), lasting more than 1 week; or more than 5 depressive symptoms lasting more than 1 week but less than 2 weeks (i.e., not meeting criteria for a major depressive episode) (by DSM-5 Clinical Semi-Definitive Interview (K-SADS-PL) (Gilbody et al., 2017, JAMA); * 4\) Hamilton Depression Scale (HAMD-24) 24 points≥ 8 points, \< 24 points; * 5\) Gender is not limited; * 6\) Subjects and their families voluntarily participate and sign the informed consent form. Exclusion Criteria: * 1\) Individuals with the following diagnoses according to DSM-5: psychiatric disorders due to organic diseases, substance-related and addictive disorders, neurodevelopmental disorders, schizophrenia spectrum and other psychotic disorders, bipolar disorder (assessed by K-SADS-PL); * 2\) Have two or more DSM-V-defined manic symptoms for 4 days but do not meet the criteria for hypomania or meet the DSM-V defined criteria for hypomanic symptoms for only 2-3 days; * 3\) Severe or unstable physical illness; * 4\) have a moderate or higher risk of suicide (as assessed by the Columbia Suicide Severity Scale); * 5\) Received transcranial direct current stimulation in the past three months (continuous intervention time: \>2 weeks); * 6\) Contraindications to transcranial direct current stimulation, such as brain implants, personal or family history of epilepsy; * 7\) Magnetic resonance scanning is contraindicated, such as in vivo metal implants.

Contact & Investigator

Central Contact

Kangguang Lin, M.D;Ph.D

✉ linkangguang@163.com

📞 86-02081268189

Principal Investigator

Kangguang Lin, M.D;PH.D

STUDY DIRECTOR

The Affiliated Brain Hospital of Guangzhou Medical University

Frequently Asked Questions

Who can join the NCT06294184 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 25 Years, studying Subthreshold Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06294184 currently recruiting?

Yes, NCT06294184 is actively recruiting participants. Contact the research team at linkangguang@163.com for enrollment information.

Where is the NCT06294184 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06294184 clinical trial?

NCT06294184 is sponsored by Guangzhou Psychiatric Hospital. The principal investigator is Kangguang Lin, M.D;PH.D at The Affiliated Brain Hospital of Guangzhou Medical University. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology